Defects in IFNγ signaling (which also prevent IFNγ-induced MHC expression) have been identified in 4–10% of PD1-resistant melanomas and are often due to loss-of-function mutations in the IFNγ effector kinases JAK1 and JAK29,16. The gene discussed is JAK1; the disease is melanoma.